Bank of New York Mellon Corp reduced its stake in Edwards Lifesciences Corp. (NYSE:EW) by 1.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,835,925 shares of the medical research company’s stock after selling 19,674 shares during the period. Bank of New York Mellon Corp owned 0.86% of Edwards Lifesciences Corp. worth $221,340,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of EW. CenturyLink Investment Management Co bought a new position in Edwards Lifesciences Corp. during the second quarter valued at approximately $207,000. British Columbia Investment Management Corp increased its position in Edwards Lifesciences Corp. by 11.7% in the second quarter. British Columbia Investment Management Corp now owns 145,782 shares of the medical research company’s stock valued at $14,539,000 after buying an additional 15,291 shares during the period. Exxonmobil Investment Management Inc. TX increased its position in Edwards Lifesciences Corp. by 4.9% in the second quarter. Exxonmobil Investment Management Inc. TX now owns 54,815 shares of the medical research company’s stock valued at $5,467,000 after buying an additional 2,566 shares during the period. Capstone Asset Management Co. increased its position in Edwards Lifesciences Corp. by 10.2% in the second quarter. Capstone Asset Management Co. now owns 26,363 shares of the medical research company’s stock valued at $2,629,000 after buying an additional 2,432 shares during the period. Finally, Pure Financial Advisors Inc. increased its position in Edwards Lifesciences Corp. by 17.8% in the second quarter. Pure Financial Advisors Inc. now owns 4,118 shares of the medical research company’s stock valued at $411,000 after buying an additional 623 shares during the period. 83.08% of the stock is currently owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Edwards Lifesciences Corp. (NYSE:EW)

Edwards Lifesciences Corp. (NYSE:EW) opened at 82.85 on Thursday. The stock has a market capitalization of $17.71 billion, a P/E ratio of 32.75 and a beta of 0.71. Edwards Lifesciences Corp. has a 52 week low of $72.20 and a 52 week high of $121.75. The company’s 50-day moving average price is $99.49 and its 200 day moving average price is $106.55.

Edwards Lifesciences Corp. (NYSE:EW) last issued its quarterly earnings data on Tuesday, October 25th. The medical research company reported $0.68 earnings per share for the quarter, hitting the consensus estimate of $0.68. The company earned $739.40 million during the quarter, compared to analyst estimates of $749.14 million. Edwards Lifesciences Corp. had a return on equity of 24.32% and a net margin of 19.24%. The firm’s revenue for the quarter was up 20.1% compared to the same quarter last year. During the same period in the prior year, the business posted $0.54 earnings per share. Equities research analysts expect that Edwards Lifesciences Corp. will post $2.88 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was posted by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are accessing this article on another site, it was illegally copied and republished in violation of US and international trademark and copyright law. The original version of this article can be accessed at https://www.thecerbatgem.com/2016/12/01/bank-of-new-york-mellon-corp-sells-19674-shares-of-edwards-lifesciences-corp-ew.html.

Several analysts recently issued reports on the company. Zacks Investment Research cut Edwards Lifesciences Corp. from a “buy” rating to a “hold” rating in a research report on Friday, August 5th. Canaccord Genuity reiterated a “buy” rating and set a $140.00 target price on shares of Edwards Lifesciences Corp. in a research report on Thursday, August 18th. Evercore ISI reiterated a “hold” rating and set a $115.00 target price on shares of Edwards Lifesciences Corp. in a research report on Friday, August 19th. Credit Suisse Group AG set a $116.00 target price on Edwards Lifesciences Corp. and gave the stock a “buy” rating in a research report on Thursday, August 18th. Finally, Morgan Stanley reiterated a “buy” rating and set a $140.00 target price on shares of Edwards Lifesciences Corp. in a research report on Friday, August 19th. One analyst has rated the stock with a sell rating, five have given a hold rating and twenty-two have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $117.28.

In other news, CEO Michael A. Mussallem sold 49,100 shares of the firm’s stock in a transaction on Thursday, October 27th. The stock was sold at an average price of $92.77, for a total transaction of $4,555,007.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Huimin Wang sold 13,650 shares of the firm’s stock in a transaction on Tuesday, September 6th. The stock was sold at an average price of $115.72, for a total value of $1,579,578.00. The disclosure for this sale can be found here. 2.37% of the stock is owned by corporate insiders.

About Edwards Lifesciences Corp.

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company manufactures heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. It develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting.

5 Day Chart for NYSE:EW

Receive News & Stock Ratings for Edwards Lifesciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corp. and related stocks with our FREE daily email newsletter.